The Effects of Alpha Lipoic Acid and Vitamin B6 on Patients with Chemotherapy Induced Peripheral Neuropathy

2.50
Hdl Handle:
http://hdl.handle.net/10755/164961
Category:
Abstract
Type:
Presentation
Title:
The Effects of Alpha Lipoic Acid and Vitamin B6 on Patients with Chemotherapy Induced Peripheral Neuropathy
Author(s):
Flores, Eleanor; Kathleen Haley
Author Details:
Eleanor Flores, RN, FNP-BC, AOCNP, Nurse Practitioner, Clinical Director, San Diego Pacific Oncology and Hematology Associates, La Jolla, California, USA, email: ellieflores@hotmail.com; Kathleen Haley, RN, FNP-BC, AOCNP
Abstract:
Research Study: Peripheral neuropathy is a common side effect among cancer patients being treated with various chemotherapy agents. This chemotherapy induced peripheral neuropathy (CIPN) often impacts patients' quality of life (QOL) while also limiting treatment options and optimal drug dosing. No one treatment has been found to greatly improve symptoms of CIPN. For these reasons, ONS has identified the need for research in the area of identifying and treating peripheral neuropathy. Two vitamins that may show promise in treating CIPN are alpha-lipoic acid (ALA) and vitamin B6. Research has shown these two vitamins play an important role in neurologic processes in the body. The purpose of this study was to explore the effects of ALA and B6 on patients with CIPN and its impact on their QOL. QOL has become an important measurement in determining successful cancer treatment and the driving force behind this research. Ferrell's QOL Model identifies four major components of QOL: physical, social, psychological, and spiritual well-being. This model was used as the theoretical framework, as the effects of CIPN on a patient disrupts QOL by impacting both physical and social aspects of life. This retrospective, qualitative study was conducted in a private oncology office. The convenience sample of ten patients who had taken ALA and B6 for CIPN were asked to participate. Data collection consisted of chart reviews and patient interviews. Grading of the CIPN was based on the National Cancer Institute Toxicity Scale. QOL functional status was assessed utilizing components of the Dartmouth Primary Cooperative Group Information Project Tool. The study was approved by the Institutional Review Board and patient consent was obtained before conducting the interviews. Results showed a decrease in the severity of CIPN in these patients with improved numbers in the NCI Toxicity Scale as well as the Dartmouth Functional Scales. Personal patient accounts of improvement in their CIPN were impressive. This small qualitative study is an important step to understanding the benefits of ALA and B6 in improving CIPN symptoms. A more objective and controlled study is warranted to statistically confirm these findings.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2009
Conference Name:
34th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
San Antonio, Texas, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleThe Effects of Alpha Lipoic Acid and Vitamin B6 on Patients with Chemotherapy Induced Peripheral Neuropathyen_GB
dc.contributor.authorFlores, Eleanoren_US
dc.contributor.authorKathleen Haleyen_US
dc.author.detailsEleanor Flores, RN, FNP-BC, AOCNP, Nurse Practitioner, Clinical Director, San Diego Pacific Oncology and Hematology Associates, La Jolla, California, USA, email: ellieflores@hotmail.com; Kathleen Haley, RN, FNP-BC, AOCNPen_US
dc.identifier.urihttp://hdl.handle.net/10755/164961-
dc.description.abstractResearch Study: Peripheral neuropathy is a common side effect among cancer patients being treated with various chemotherapy agents. This chemotherapy induced peripheral neuropathy (CIPN) often impacts patients' quality of life (QOL) while also limiting treatment options and optimal drug dosing. No one treatment has been found to greatly improve symptoms of CIPN. For these reasons, ONS has identified the need for research in the area of identifying and treating peripheral neuropathy. Two vitamins that may show promise in treating CIPN are alpha-lipoic acid (ALA) and vitamin B6. Research has shown these two vitamins play an important role in neurologic processes in the body. The purpose of this study was to explore the effects of ALA and B6 on patients with CIPN and its impact on their QOL. QOL has become an important measurement in determining successful cancer treatment and the driving force behind this research. Ferrell's QOL Model identifies four major components of QOL: physical, social, psychological, and spiritual well-being. This model was used as the theoretical framework, as the effects of CIPN on a patient disrupts QOL by impacting both physical and social aspects of life. This retrospective, qualitative study was conducted in a private oncology office. The convenience sample of ten patients who had taken ALA and B6 for CIPN were asked to participate. Data collection consisted of chart reviews and patient interviews. Grading of the CIPN was based on the National Cancer Institute Toxicity Scale. QOL functional status was assessed utilizing components of the Dartmouth Primary Cooperative Group Information Project Tool. The study was approved by the Institutional Review Board and patient consent was obtained before conducting the interviews. Results showed a decrease in the severity of CIPN in these patients with improved numbers in the NCI Toxicity Scale as well as the Dartmouth Functional Scales. Personal patient accounts of improvement in their CIPN were impressive. This small qualitative study is an important step to understanding the benefits of ALA and B6 in improving CIPN symptoms. A more objective and controlled study is warranted to statistically confirm these findings.en_GB
dc.date.available2011-10-27T12:10:05Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:10:05Z-
dc.conference.date2009en_US
dc.conference.name34th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationSan Antonio, Texas, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.